Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
882.4 INR | +4.31% | +5.40% | +36.12% |
Apr. 09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
Jan. 30 | Transcript : Strides Pharma Science Limited, Q3 2024 Earnings Call, Jan 30, 2024 |
Sales 2024 * | 41.14B 494M | Sales 2025 * | 45.13B 542M | Capitalization | 77.53B 931M |
---|---|---|---|---|---|
Net income 2024 * | -414M -4.97M | Net income 2025 * | 2.92B 35.08M | EV / Sales 2024 * | 1.88 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.72 x |
P/E ratio 2024 * |
-183
x | P/E ratio 2025 * |
20.8
x | Employees | 2,850 |
Yield 2024 * |
0.43% | Yield 2025 * |
0.43% | Free-Float | 68.29% |
Latest transcript on Strides Pharma Science Limited
1 day | +4.34% | ||
1 week | +5.40% | ||
Current month | +12.78% | ||
1 month | +14.23% | ||
3 months | +35.27% | ||
6 months | +81.75% | ||
Current year | +36.12% |
Managers | Title | Age | Since |
---|---|---|---|
Arun N. Kumar
CEO | Chief Executive Officer | 63 | 90-06-27 |
Badree Komandur
DFI | Director of Finance/CFO | - | 10-01-31 |
Compliance Officer | - | 17-02-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arun N. Kumar
CEO | Chief Executive Officer | 63 | 90-06-27 |
Director/Board Member | 80 | 17-05-17 | |
Director/Board Member | 63 | 12-07-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 882.4 | +4.31% | 34 571 |
24-04-22 | 845.9 | +0.34% | 10,651 |
24-04-19 | 843 | -0.12% | 26,553 |
24-04-18 | 844 | +0.79% | 10,676 |
24-04-16 | 837.4 | +1.25% | 7,013 |
Delayed Quote Bombay S.E., April 23, 2024 at 05:06 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.75% | 44.31B | |
+19.87% | 22.17B | |
+14.82% | 14.62B | |
+9.02% | 13.12B | |
+39.50% | 11.58B | |
-8.96% | 6.96B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.50% | 5.03B |
- Stock Market
- Equities
- STAR Stock
- STAR Stock